Kuznicki Law is investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK. Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the transaction is structured as a tender offer, such that time may be of the essence.